Targeting ERα Coregulator Networks to Overcome Endocrine Resistance in ER+ Breast Cancer

Area of Science:

• Oncology
• Endocrinology
• Molecular Biology

Background:

• Breast cancer (BC) is a leading global cancer in women, with 70% being estrogen receptor-positive (ER+).
• Endocrine therapies are standard for ER+ BC but face challenges from intrinsic and acquired resistance.
• Aberrant expression of ERα coregulators can drive ligand-independent ER activation, contributing to treatment resistance.

Purpose of the Study:

• To review the role of ERα coregulators in endocrine resistance in ER+ breast cancer.
• To critically evaluate the therapeutic potential of targeting ERα coregulators.
• To provide guidance for the clinical development of ERα coregulator-targeting strategies.

Main Methods:

• Literature review synthesizing current evidence on ERα coregulators and endocrine resistance.
• Critical assessment of the therapeutic potential of targeting ERα coregulators.
• Analysis of molecular mechanisms underlying endocrine resistance.

Main Results:

• ERα coregulators play a significant role in the development of endocrine resistance in ER+ breast cancer.
• Targeting ERα coregulators is a promising therapeutic strategy to overcome endocrine resistance.
• Understanding coregulator function is key to improving treatment efficacy.

Conclusions:

• ERα coregulators are critical mediators of endocrine resistance in ER+ breast cancer.
• Targeting these coregulators offers a viable approach to overcome treatment resistance.
• Further research into molecular mechanisms is essential for advancing therapeutic strategies.